Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Nidanilimab |
Synonyms | |
Therapy Description |
Nidanilimab is a humanized monoclonal antibody that targets ll1rap, which inhibits downstream signaling and blocks activation of NFkappa-B, thereby potentially inducing antibody-dependent cellular cytotoxicity, leading to decreased proliferation and increased death of tumor cells expressing IL1RAP (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Nidanilimab | CAN04|CAN 04|CAN-04|Nadunolimab | Nidanilimab is a humanized monoclonal antibody that targets ll1rap, which inhibits downstream signaling and blocks activation of NFkappa-B, thereby potentially inducing antibody-dependent cellular cytotoxicity, leading to decreased proliferation and increased death of tumor cells expressing IL1RAP (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06548230 | Phase Ib/II | Azacitidine + Nidanilimab + Venetoclax Nidanilimab | A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML) | Not yet recruiting | USA | 0 |
NCT03267316 | Phase Ib/II | Nidanilimab Cisplatin + Gemcitabine + Nidanilimab Gemcitabine + Nab-paclitaxel + Nidanilimab | A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors (CANFOUR) | Completed | SWE | NOR | NLD | LVA | LTU | EST | ESP | DNK | DEU | BEL | AUT | 0 |